Browse the evidence

Increased accelerometry-measured MVPA from baseline to year 4 is associated with decreased risk of CVD outcomes.

Long-term engagement in MVPA is crucial for reducing CVD risk in this demographic.

Use of GLP‐1 or GLP‐1/GIP RA therapy after lung transplantation was effective at decreasing weight and improving hemoglobin A1c.

Practitioners can consider GLP-1 and GLP-1/GIP RA therapies for weight management and glycemic control in lung transplant patients.

Semaglutide led to a mean relative weight loss of 13.3 ± 11.3% after 12 months in adults with type 1 diabetes.

Practitioners can consider semaglutide as an effective option for weight management in overweight/obese patients with type 1 diabetes.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) decreased from 82.6% to 30.4% after treatment with semaglutide.

Semaglutide may significantly improve liver health in patients with type 1 diabetes and MASLD.

Adding semaglutide to usual care in US adults without diabetes is projected to avert 358,400 major adverse cardiovascular events (MACE) at a cost of $148,100 per quality-adjusted life-year (QALY) gained.

Semaglutide may be a beneficial addition to treatment plans for eligible patients to reduce cardiovascular risks.

Lifestyle intervention combined with older obesity medications is associated with approximately 5%-10% weight loss.

Combining lifestyle changes with medications can enhance weight loss outcomes for patients.

GLP-1 analogs have shown efficacy in improving weight loss and cardiovascular risk factors.

Practitioners may consider GLP-1 analogs as a treatment option for weight management in menopausal women.

Initiation of semaglutide was significantly associated with a -3.8% reduction in weight at 13 to 24 months.

Semaglutide may be an effective option for weight management in adults.

Patients can achieve significant weight reduction with the fixed-dose, extended-release combination of naltrexone and bupropion (NB-ER) compared with placebo when combined with a reduced-calorie diet and increased physical activity.

Practitioners should consider prescribing NB-ER for patients with obesity who are also engaging in dietary and physical activity changes.

The appropriate use of NB-ER should consider the specific characteristics and adiposity-related complications of an individual.

Practitioners should assess individual patient characteristics when prescribing NB-ER.

Tirzepatide is effective in glucose control and weight reduction.

Tirzepatide can be considered a viable option for improving glycemic control and aiding weight loss in diabetic patients.

A prolonged lapse in GLP-1 receptor agonist therapy warrants consideration of reinitiation at a reduced dose.

Practitioners should consider starting patients on a reduced dose after a significant therapy lapse.

Incretin agonist therapies improve type 2 diabetes outcomes and cardiovascular mortality.

Incretin agonists may be a viable alternative to surgery for managing diabetes and cardiovascular risks.

Tirzepatide is effective in reducing body weight and controlling blood glucose levels.

Tirzepatide can be considered a viable treatment option for patients struggling with weight and blood glucose management.

Tirzepatide has been approved by the FDA for treating T2D and managing chronic weight in overweight or obese patients.

Healthcare providers can confidently prescribe tirzepatide for eligible patients based on FDA approval.

Resistance training volume is suggested to be one of the most effective variables for developing muscular hypertrophy.

Practitioners should consider resistance training volume as a key factor in designing hypertrophy-focused training programs.

Controlling for each individual's previous training volume could improve the precision of the muscle hypertrophic response to resistance training.

Practitioners should assess an individual's training history to tailor resistance training programs for optimal muscle growth.

Lifestyle modification can provide glycemic benefits to prevent type 2 diabetes (T2D) and its comorbidities.

Practitioners should encourage lifestyle modifications as a standard approach to prevent T2D.

Velocity-based training (VBT) at 2 or 3 days per week significantly improves muscle morphology in patients with Parkinson's disease.

Practitioners can implement VBT in exercise programs for patients with Parkinson's disease to enhance muscle morphology.

VBT improves neuromuscular performance and functional capability in patients with Parkinson's disease.

Incorporating VBT can enhance both performance and functional abilities in Parkinson's patients.

Improvements in maximal gait speed require a frequency of 3 days per week of VBT.

To maximize gait speed improvements, practitioners should recommend VBT at 3 days per week for Parkinson's patients.

Adopting MLCDs, particularly those with sufficient fiber content, can reduce the risk of cardiovascular diseases in patients suffering from dyslipidemia.

Practitioners may consider recommending MLCDs with sufficient fiber to patients with dyslipidemia to help reduce cardiovascular risks.

Soy isoflavones can significantly contribute to lowering metabolic risk and affect hormonal balance in women with PCOS.

Incorporating soy isoflavones may be beneficial for women with PCOS in managing metabolic and hormonal issues.

The Mediterranean diet is advised for cardiovascular prevention in patients with familial hypercholesterolemia (FH).

Practitioners should consider recommending the Mediterranean diet to patients with FH.